Imagine your child's life hanging by a thread, doctors baffled, hope dwindling... That's exactly what Ian Gillies Sr. faced when his son, Ian Jr., became mysteriously ill. But this isn't just a story of a medical crisis; it's a testament to the power of relentless curiosity and a first-year resident's determination to solve the unsolvable. Get ready to discover how a young doctor in St. John's, Newfoundland, cracked a rare disease case and sparked a global medical breakthrough.
Ian Gillies Sr. still finds it incredibly difficult to look at the photographs he took during his son's harrowing two-month stay at the Health Sciences Centre in St. John's. The memories are vivid enough, and for now, he prefers to focus on the future. "We've been through hell and back, and it really gives you a different perspective on life," he reflects.
That "hell" began in the summer of 2023. Ian Gillies Jr., fresh out of the College of North Atlantic, was strangely devoid of energy. This wasn't just typical post-graduation fatigue. The 22-year-old felt so profoundly drained that he eventually couldn't even manage the stairs in the Conception Bay South home he shared with his father.
"It got to the point where I was bringing him to the doctor in a wheelchair," Gillies Sr. recalls, the helplessness still evident in his voice.
Adding to the misery, Ian Jr. suffered from severe constipation and debilitating bloating. He spent hours soaking in their hot tub, desperately seeking relief from the agonizing pain. "It was like a warm compress, providing temporary comfort," he explained.
The situation took a dramatic turn one October day when their family doctor called with alarming test results, urging them to rush to the emergency room immediately. In just one month, Ian Jr. had gained nearly 60 pounds as his body relentlessly retained fluid.
Now, in the world of medicine, there's a common saying: "When you hear hoofbeats, look for horses, not zebras." This means doctors should first consider common ailments before jumping to rare diagnoses. But what happens when it is a zebra? This is a story about exactly that, and how a doctor's perseverance put east coast research on a global map.
Inside the hospital, the Gillies family meticulously tracked Ian Jr.'s charts, clinging to any sign of improvement. "Every day, we'd watch the numbers going down, and down, and down," Gillies Sr. recounts, his voice heavy with the memory.
Despite their best efforts, the medical experts ruled out the usual suspects: cancers, infections, and common autoimmune disorders. They drained liters upon liters of fluid accumulating around his abdomen – roughly equivalent to 15 two-liter milk cartons over several weeks. Gillies Sr. remembers painstakingly helping his son to the bathroom, navigating the maze of wires and tubes.
Strangely, Ian Jr. has little recollection of this period. "The whole time was spent in the same bed, in the same room, with the same people around. So it all just melds together into one big blur," he explains.
Despite the fog of illness, one ominous trend was undeniable: a month into the ordeal, Ian Jr.'s condition was rapidly deteriorating.
"The doctors were telling us he might not make it through the night," Gillies Sr. says, his voice cracking with emotion. "And then a savior came along."
That "savior" arrived on a seemingly ordinary Monday. But to be fair, this medical hero had already begun his work the night before, diligently studying his new case files late into the night. Dr. Steven Rowe, a first-year internal medicine resident from Memorial University, was starting his first rotation.
"You don't want to show up in the morning empty-handed, not knowing anything about your patient," Dr. Rowe explains, emphasizing his commitment to thorough preparation.
Ian Jr.'s file presented a complex and alarming picture: dangerously low blood counts, swollen lymph nodes, an enlarged spleen, and failing kidneys. He was struggling to breathe and required large amounts of supplemental oxygen. The medical team wanted to perform a biopsy on one of Ian Jr.'s lymph nodes, but they were too small to safely do so.
"With anybody that's very sick, there's a lot of pressure and a lot of drive to find out what's going on and help them," Dr. Rowe says. "But I think it feels even more magnified when you have a very young person."
Dr. Rowe dedicated his precious off-duty hours to intensive research, immersing himself in medical literature. In his own words, he was "being kind of a nerd."
His dedication paid off around 11 p.m. one night when he stumbled upon a description of a rare subtype of Castleman disease called TAFRO syndrome.
"It really was exactly what was going on with Ian… it really just fit like a glove," Dr. Rowe recalls, the excitement still palpable in his voice.
Fueled by this breakthrough, the resident practically leaped out of bed, scribbling down his thoughts and observations, much to the bewilderment of his exhausted girlfriend.
"I said, you got to understand, this is a Eureka moment!" Dr. Rowe laughs.
The next morning, Dr. Rowe shared his findings with his superiors. The medical team then presented the possibility of Castleman disease to the family – coincidentally, Ian Jr.'s mother had also begun to suspect the same condition.
"He was in at like eight in the morning, and he busted the door, like eager and happy… he goes, 'I found it!'" Gillies Sr. recalls, his voice filled with gratitude.
"Everything changed that day."
Both Castleman disease and its subtype, TAFRO, are exceptionally rare. TAFRO was only first identified in 2010, and it affects approximately one in every one million people. Dr. Rowe explains that Ian Jr. was the first recognized case in Newfoundland and Labrador, which is a significant reason why the medical team didn't initially consider it.
"You pretty much never see it, even if people did know to look for it," Dr. Rowe says, highlighting the diagnostic challenge.
As the family and the St. John's medical team collaborated with Canadian and global experts to confirm the diagnosis, they realized the grave danger Ian Jr. was in.
With TAFRO, "all of a sudden, your immune system starts attacking your body as if your body were a threat," Dr. Rowe explains. "And essentially, your immune system starts to destroy all of your organs, which sounds bad. And it is."
Untreated, TAFRO carries a mortality rate of roughly 30 percent, according to Dr. Rowe. Fortunately, Ian Jr. responded positively to a novel treatment: siltuximab, administered intravenously.
The family was relieved, but understandably cautious. "Where it was something new and something rare… I was very apprehensive. You know what? I think I still am," Gillies Sr. admits.
However, Ian Jr.'s condition stabilized, and he was eventually discharged in time to spend Christmas at home. Since then, he undergoes regular blood work and siltuximab infusions. While his treatment schedule sometimes interferes with his pursuit of a new university degree, he emphasizes that being asymptomatic and healthy makes it all worthwhile.
"It's crazy, but I'm good. I'm glad it's at bay," Ian Jr. says, his voice filled with optimism.
But the story doesn't end there. It’s not just about diagnosis, but about action.
Neither the Gillies family nor Dr. Rowe wanted others to endure the same diagnostic ordeal. The family approached Dr. Rowe with a heartfelt plea: could anything be done to raise awareness about Castleman and TAFRO, enabling earlier diagnoses for future patients?
With the Gillies' enthusiastic support, Dr. Rowe collaborated with colleagues to write a detailed case report, which was published in the prestigious Canadian Medical Association Journal.
While researching that report, Dr. Rowe noticed a striking pattern: the TAFRO syndrome patients he studied shared remarkably similar bloodwork results. "Could this be something that actually helps diagnose the disease quicker?" he wondered.
Working in collaboration with colleagues and under the guidance of Dr. Luke Chen, the leading Canadian expert in the field (who had consulted on Ian Jr.'s case and is based at Dalhousie University), Dr. Rowe began to investigate this possibility.
He boldly cold-emailed the University of Pennsylvania's medical school – an Ivy League institution renowned for its Castleman disease expert, Dr. David Fajgenbaum, who had also consulted on Ian Jr.'s diagnosis – and gained access to their TAFRO patient database.
Dr. Chen shared his database of patients with another rare blood disease in the same category as Castleman, called HLH (hemophagocytic lymphohistiocytosis). Both diseases are classified as "cytokine storm syndromes," a term that gained public recognition during the COVID-19 pandemic. Crucially, HLH and TAFRO require vastly different treatments.
Rowe, along with experts in data analysis, began comparing the two sets of patients. The results were astonishing. They discovered that a common blood test – one readily available in any rural hospital or small community clinic in Newfoundland – could differentiate between TAFRO syndrome and HLH with nearly 99 percent certainty.
"This was a really important finding… and I think it's going to be quite influential in the way that people diagnose these diseases," Dr. Chen emphasizes.
The speed of diagnosis is paramount. "These patients often really don't have time," Dr. Rowe explains. "They're racing against the clock as their organs fail."
Dr. Rowe estimates that using this simple blood test to distinguish between the two diseases could reduce the time to diagnosis from one or two weeks to just one or two days.
This speed could save lives.
"Every province, every major city has the medications we use to treat TAFRO… it's just a tragedy when someone suffers or dies, and the treatment that will help turn them around is actually just sitting right there in the pharmacy, right?" Dr. Chen points out.
"We just have to connect them to the right diagnosis, and thereby to the correct treatment."
The groundbreaking study was published in the prestigious American Journal of Hematology, with Dr. Rowe as a lead author. The collaborative effort involved researchers from Memorial and Dalhousie Universities, the University of British Columbia, and the University of Pennsylvania.
To put this achievement into perspective, Dr. Chen notes that UPenn is a top-five medical research institution globally, while Dalhousie and Memorial Universities rank somewhere between 400 and 600.
"So, it's pretty good for a trainee from Memorial to be the lead author on a project like that," he says, adding that he's received enthusiastic feedback from experts as far away as Beijing.
Dr. Chen and Dr. Rowe are currently collaborating on a number of other rare disease research projects.
Looking back on that first case with Ian Jr., Dr. Rowe reflects: "I feel that kind of going the extra mile, and just spending night after night reading and not letting it go… having arrived at a diagnosis where you could get a treatment that works really well – it's just profound."
And Ian Jr. and his family will never forget those efforts.
"I went from nothing, to a whole life."
This incredible story highlights the power of dedication, collaboration, and a relentless pursuit of answers in the face of medical mysteries. What do you think about the role of young doctors in making significant breakthroughs? Do you believe that access to patient data should be more readily available for research purposes, even across international borders? Share your thoughts in the comments below.
